Ariad Pharmaceuticals, Inc.

  • Did a Strong New Drug Make This Biotech Overvalued?

    By Brandy Betz - August 16, 2013 | Tickers: AEGR, ARIA, SNTS

    Santarus (NASDAQ: SNTS) has risen over 300% in the past year partly based on sales optimism for ulcerative colitis drug Uceris, which launched in the first quarter. The company already had four products on the market and has a trio of pipeline projects in development. Is now a good time to buy Santarus -- or has it become overvalued?

    Strong second quarter

    Second quarter revenues at Santarus grew 89% year-over-year to more »

  • Did Q2 Prove This Biotech Is Overvalued?

    By Brandy Betz - August 13, 2013 | Tickers: AEGR, ARIA, NVS, SNTS

    Ariad Pharmaceuticals (NASDAQ: ARIA) reported its second quarter results last week and focused the associated conference call on the company’s two drugs. Leukemia drug Iclusig is growing in sales but faces a market saturated with generics and a long-standing blockbuster from Novartis (NYSE: NVS).  And the oncologic pipeline project lost out on a Food and Drug Administration acceleration, which will put it further behind the competition.  

    Are Ariad’s more »

  • An Under-the-Radar Drug Launch That's Producing Massive Gains

    By Brian Nichols - August 13, 2013 | Tickers: AMRN, ARIA, SNTS

    Ariad Pharmaceuticals’ (NASDAQ: ARIA) Iclusig and Amarin Corporation’s (NASDAQ: AMRN) Vascepa may have been two of the most hyped drugs of the last few years, but Uceris from Santarus (NASDAQ: SNTS) has stolen the spotlight. This is a drug that is beating all sales expectations, and leading some to wonder if Santarus’ impressive stock rally can continue.

    Three Drugs With Different Outlooks

    The reason that these three companies, and more »

  • 3 Earning Catalysts That Could Push This Biotech Even Higher

    By Sherrie Stone - July 24, 2013 | Tickers: ARIA, JAZZ, SNTS

    Santarus (NASDAQ: SNTS) has traded higher by 250% over the last year, and much of those gains have been created after the company’s last two quarterly reports. The company is scheduled to report earnings in two weeks, and will be closely watched. Here are three things that Santarus must prove in order to continue its epic trend higher.

    The Big Driver Of Success

    In Q1, $66.1 million of more »

  • Will This Biotech Acquisition Buzz Lead to More Buyouts?

    By Sherrie Stone - July 8, 2013 | Tickers: ARIA, ONXX, PCYC

    Onyx Pharmaceuticals (NASDAQ: ONXX) is trading higher after rejecting a takeover bid. As other stocks in its sector also trade higher in sympathy, will any of them become takeover targets, too?

    What’s Creating The Buzz

    The analysts, bloggers, and columnists were out in full force last Monday morning to assess the true “worth” of Onyx. The company markets cancer drugs Nexavar and Stivarga with Bayer, and solely develops Kyprolis more »

  • Celldex On The Rise

    By Terry Chrisomalis - July 3, 2013 | Tickers: ARIA, CLDX, SGEN

    There are many biotech stocks that target cancer, but what is good about Celldex Therapeutics (NASDAQ: CLDX) is that it is targeting many therapeutic areas as well as cancer. Celldex has gone up over 209% in one year. The reason for the rise is the results that the company has been putting out about its drug candidates, especially two of them. The company has diversified its pipeline into targeting cancers more »

  • Should You Buy the Hype Surrounding This Product Launch?

    By Sherrie Stone - July 1, 2013 | Tickers: AMRN, ARIA, GALE, VVUS

    While the analysis of peak sales and potential patient populations may be appealing to most, it costs a great deal of money to launch a new product with success. In the case of Galena Biopharma (NASDAQ: GALE), the company doesn’t have the cash, but touts tremendous sales potential, so might the company succeed anyway?

    The reality of launching drugs in healthcare

    I would like to share with you something more »

  • What’s Moving These Biotech Stocks?

    By Brian Nichols - May 18, 2013 | Tickers: ARIA, INFI, ONTY

    As one of the most important conferences in biotechnology approaches (ASCO) we are seeing wild swings of volatility. On Thursday there were several stocks that moved to the downside, and in this piece I am determining if any are a buy after the large moves.

    Ariad Pharmaceuticals (NASDAQ: ARIA)

    Shares of Ariad Pharmaceuticals fell more than 4% after a report from Fox News suggested that cancer patients are now electing more »

  • These 3 Biotech Stocks Look Interesting

    By Shas Dey - April 30, 2013 | Tickers: ARIA, ARRY, CLDX

    Three biotech companies are making themselves heard in the stock market. They are making a mark in the life sciences space with their unique mix of science and strategy.

    Ariad Pharmaceuticals (NASDAQ: ARIA) is on the focused approach trajectory, using its solid foundation in the sciences to fill the holes left open by big pharma. Celldex Therapeutics (NASDAQ: CLDX) is exercising first-mover advantage by developing a novel but potent approach more »

  • Under-the-Radar Hedge Fund Focusing on Pharma

    By Meena Krishnamsetty - March 20, 2013 | Tickers: ARIA, PODD, PCYC, YMI.DL

    Hedge funds are typically thought of as being billion dollar funds managed by Harvard MBAs and alums of some of Wall Street’s more prestigious analyst programs (i.e. Goldman Sachs, JP Morgan). Interestingly, Dafna Capital Management is rather small (only $63 million) and is managed by Dr. Nathan Fischel MD and his wife, a biomedical engineer. So why are we even talking about Dafna? Because according to the most more »

  • Billionaire Dan Loeb, Third Point Making Moves Last Quarter

    By Meena Krishnamsetty - February 18, 2013 | Tickers: ABT, ABBV, AAPL, ARIA, EA

    In the hedge fund universe, 13F filing season is here, and we’re bringing you up-to-date coverage of this situation. Our research has shown that hedgies’ consensus small-cap stock picks beat the market by 18 percentage points per year (use our market-beating strategy). Last year the most popular large cap stocks among billionaire fund managers outperformed the S&P 500 index by 8 percentage points as well. Dan Loeb is more »

  • Five Amazing Biotech Picks with Futuristic Technology

    By Streetwise Reports - January 29, 2013 | Tickers: ARIA, ASTX, GALE, SRPT

    Michael King is looking for the monoclonal antibodies of tomorrow. When I first spoke to him 15 or more years ago, King was talking up Immunex, which would later be taken out by Amgen for $16 billion for its anti-tumor necrosis factor (anti-TNF) fusion protein Enbrel (etanercept) to treat rheumatoid arthritis. Today Amgen’s (via Immunex) Enbrel and the anti-TNF monoclonal antibodies that would follow-- Johnson & Johnson’s Remicade (infliximab more »

  • Billionaire Steve Cohen’s Most Promising Stock Picks

    By Meena Krishnamsetty - January 12, 2013 | Tickers: ARIA, ENDP, NCR, SPN, VC

    Small-cap and mid-cap stocks don’t get as much attention from bankers, third-party analysts, and the media, which often leaves them less efficiently priced than large- and mega-caps. Hedge funds sometimes take advantage of this by dedicating their research teams to work on these lower valuation stocks as well, and so often earn substantial alpha from their investments. Retail investors can use smaller-cap stocks that hedge funds reported owning as more »

  • Big Wave Trading Portfolio Update And Top Current Holdings

    By Joshua Hayes - December 14, 2012 | Tickers: ASPS, AMCC, ARIA, BBRY, CNC, FB, FSLR, GOOG, GMCR, PCLN, QCOM, SWHC

    The Big Wave Trading portfolio remains under a NEUTRAL signal. However, we did switch to a BUY signal for 2 days before switching back to NEUTRAL. Fortunately for us, we have already closed shop on our model for the year. After the final and barely successful SELL signal it was decided that with the current price/volume pattern in the overall market, the upcoming Fiscal Cliff drama, and the news more »

  • Can These Biotechs Make You Money In 2012?

    By Robert Fisher - January 14, 2012 | Tickers: ARIA, DNDN, HGSI, ILMN, MNKD

    The biotech group is among the largest in the market in terms of the number of companies. They trade with perhaps the highest volatility in the market and move heavily on optimism of future successful drugs. The five biotech stocks on my radar today are Dendreon Corp. (NASDAQ: DNDN), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Human Genome Sciences (NASDAQ: HGSI), Illumina Inc. (NASDAQ: ILMN) and MannKind Corp. (NASDAQ: MNKD). The outlook more »